Vistin Pharma ASA

As of June 30, 2026, Vistin Pharma ASA carries a market capitalization of 917.93M, placing it among publicly traded companies globally. Its enterprise value stands at 925.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Vistin Pharma ASA has 44.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Vistin Pharma ASA maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Vistin Pharma ASA recorded 14.58M in income tax expense.

As of the close on September 11, 2026, Vistin Pharma ASA's stock has declined approximately 20.17% over the past 52 weeks. The 50-day moving average sits at 22.04, while the 200-day moving average is 17.51.

As of June 30, 2026, Vistin Pharma ASA holds 7.90M in cash and equivalents against 15.52M in total debt, resulting in a net debt position of 7.63M. Total book value stands at 320.10M, with working capital of 120.99M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Vistin Pharma ASA's most recent stock split took place on March 23, 2018 with a 565:572 split ratio.